AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Natera Inc. (NTRA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

169.51

-3.88 (-2.24%)

At close: Feb 18, 2025, 3:59 PM

undefined% (undefined)

Bid	168.68
Market Cap	22.38B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.77
PE Ratio (ttm)	-95.77
Forward PE	n/a
Analyst	Buy

Ask	172
Volume	963,132
Avg. Volume (20D)	1,261,711
Open	178.00
Previous Close	173.39
Day's Range	169.11 - 180.41
52-Week Range	68.03 - 183.00
Beta	undefined

About NTRA

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; a...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Jul 1, 2015

Employees 3,282

Stock Exchange NASDAQ

Ticker Symbol NTRA

Website https://www.natera.com

Full Company Profile

Analyst Forecast

According to 17 analyst ratings, the average rating for NTRA stock is "Buy." The 12-month stock price forecast is $175, which is an increase of 3.24% from the latest price.

Buy 94.12%

Hold 5.88%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Natera Inc. is scheduled to release its earnings on Feb 27, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+1.58%

Natera shares are trading higher after the company... Unlock content with Pro Subscription

3 weeks ago

+2.67%

Natera shares are trading higher after the company announced it will reveal new insights and innovations for tissue-free MRD at ASCO GI 2025

News

1 day ago · zacks.com

Natera (NTRA) Recently Broke Out Above the 20-Day Moving Average

From a technical perspective, Natera (NTRA) is looking like an interesting pick, as it just reached a key level of support. NTRA recently overtook the 20-day moving average, and this suggests a short-...

1 week ago · businesswire.com

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecu...

2 weeks ago · 247wallst.com

Billionaire Stanley Druckenmiller says the AI boom could get much bigger – These are the stocks he owns

Stanley Druckenmiller is one of those legendary investors who are worth listening to and learning from.

2 weeks ago · businesswire.com

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD n...

3 weeks ago · businesswire.com

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

AUSTIN, Texas,--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 stud...

4 weeks ago · businesswire.com

Natera to Present New Data at the 2025 ASCO GI Symposium

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studi...

1 month ago · businesswire.com

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve Chapman, has been selected as one of the top heal...

1 month ago · businesswire.com

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter and full year end...

1 month ago · fool.com

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings

Decades away from his star-making turn at George Soros' Quantum Group of Funds, high-profile investor Stanley Druckenmiller stays well active in the stock-picking game with his Duquesne Family Office ...

1 month ago · businesswire.com

Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference in ...

Load More News